Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

NCT04886596 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

26675

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: Placebo
BIOLOGICAL: RSVPreF3 OA vaccine

Sponsor

GlaxoSmithKline